1. Home
  2. STEM vs RNTX Comparison

STEM vs RNTX Comparison

Compare STEM & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stem Inc.

STEM

Stem Inc.

HOLD

Current Price

$5.40

Market Cap

56.6M

Sector

Technology

ML Signal

HOLD

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.74

Market Cap

65.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STEM
RNTX
Founded
2009
2001
Country
United States
United States
Employees
N/A
10
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.6M
65.7M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
STEM
RNTX
Price
$5.40
$0.74
Analyst Decision
Hold
Buy
Analyst Count
3
2
Target Price
$13.33
$10.00
AVG Volume (30 Days)
102.4K
385.3K
Earning Date
05-06-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$156,266,000.00
N/A
Revenue This Year
$2.77
N/A
Revenue Next Year
$14.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.08
N/A
52 Week Low
$4.92
$0.73
52 Week High
$32.23
$2.18

Technical Indicators

Market Signals
Indicator
STEM
RNTX
Relative Strength Index (RSI) 34.12 33.10
Support Level N/A N/A
Resistance Level $8.39 $1.32
Average True Range (ATR) 0.38 0.08
MACD -0.04 -0.01
Stochastic Oscillator 27.27 8.95

Price Performance

Historical Comparison
STEM
RNTX

About STEM Stem Inc.

Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: